Compare BWMN & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMN | PRME |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.2M | 666.1M |
| IPO Year | N/A | N/A |
| Metric | BWMN | PRME |
|---|---|---|
| Price | $33.09 | $3.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $40.90 | $6.42 |
| AVG Volume (30 Days) | 117.1K | ★ 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.21 | $95.64 |
| Revenue Next Year | $9.62 | N/A |
| P/E Ratio | $35.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.90 | $1.11 |
| 52 Week High | $45.83 | $6.94 |
| Indicator | BWMN | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 40.45 |
| Support Level | $33.16 | $3.20 |
| Resistance Level | $36.67 | $3.50 |
| Average True Range (ATR) | 1.59 | 0.29 |
| MACD | -0.15 | -0.06 |
| Stochastic Oscillator | 41.92 | 14.46 |
Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.